AtaiBeckley (ATAI) Income from Continuing Operations (2020 - 2026)
AtaiBeckley (ATAI) posted quarterly Income from Continuing Operations of 29802000.0 for Q1 2026, down 12.61% year-over-year from 34101951.31 in Q1 2025, and down 12.61% quarter-over-quarter from 26465000.0 in Q1 2025.
AtaiBeckley (ATAI) Income from Continuing Operations (2020 - 2026) Analysis & Trends
AtaiBeckley has reported Income from Continuing Operations for 6 years, with the latest figure at 61067000.0 in Q3 2025.
- Quarterly Income from Continuing Operations fell 129.03% year-over-year to 61067000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 154276000.0 (down 20.36% YoY) and the FY2024 annual result came in at 148049000.0, down 267.35% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 29802000.0, down from 26465000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 26465000.0 in Q1 2025, with the low at 29802000.0 in Q1 2026.
- A 5-year average of 30429526.32 and a median of 31843000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2021 and 2023: Income from Continuing Operations plunged 842.61% in 2021, then soared 231.22% in 2023.
- Over 5 years, Income from Continuing Operations stood at 49296000.0 in 2021, then increased by 18.3% to 40276000.0 in 2022, then soared by 53.45% to 18748000.0 in 2023, then plunged by 107.97% to 38991000.0 in 2024, then plunged by 56.62% to 61067000.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 61067000.0, 27753000.0, and 26465000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | AtaiBeckley | 2.69 Bn | 2.69 Bn | - | -61.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -32.58 Mn |
| Mar 31, 2026 | -29.80 Mn |
| Sep 30, 2025 | -61.07 Mn |
| Jun 30, 2025 | -27.75 Mn |
| Mar 31, 2025 | -26.47 Mn |
| Mar 31, 2025 | -26.47 Mn |
| Dec 31, 2024 | -38.99 Mn |
| Sep 30, 2024 | -26.66 Mn |
| Jun 30, 2024 | -57.10 Mn |
| Mar 31, 2024 | -25.68 Mn |
| Dec 31, 2023 | -18.75 Mn |
| Sep 30, 2023 | 43.61 Mn |
| Jun 30, 2023 | -31.84 Mn |
| Mar 31, 2023 | -33.36 Mn |
| Dec 31, 2022 | -40.28 Mn |
| Sep 30, 2022 | -33.23 Mn |
| Jun 30, 2022 | -30.86 Mn |
| Mar 31, 2022 | -31.96 Mn |
| Dec 31, 2021 | -49.30 Mn |
| Sep 30, 2021 | -26.87 Mn |